AU2023273853A1 - Anti-b7h3 antibody and uses thereof - Google Patents

Anti-b7h3 antibody and uses thereof Download PDF

Info

Publication number
AU2023273853A1
AU2023273853A1 AU2023273853A AU2023273853A AU2023273853A1 AU 2023273853 A1 AU2023273853 A1 AU 2023273853A1 AU 2023273853 A AU2023273853 A AU 2023273853A AU 2023273853 A AU2023273853 A AU 2023273853A AU 2023273853 A1 AU2023273853 A1 AU 2023273853A1
Authority
AU
Australia
Prior art keywords
antibody
antigen
amino acid
binding portion
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023273853A
Other languages
English (en)
Inventor
Jijie Gu
Jie Li
Naiyan RONG
Zhuozhi Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuxi Biologics Ireland Ltd
Original Assignee
Wuxi Biologics Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Biologics Ireland Ltd filed Critical Wuxi Biologics Ireland Ltd
Publication of AU2023273853A1 publication Critical patent/AU2023273853A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023273853A 2022-05-18 2023-05-17 Anti-b7h3 antibody and uses thereof Pending AU2023273853A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/093524 2022-05-18
CN2022093524 2022-05-18
PCT/CN2023/094711 WO2023222017A1 (en) 2022-05-18 2023-05-17 Anti-b7h3 antibody and uses thereof

Publications (1)

Publication Number Publication Date
AU2023273853A1 true AU2023273853A1 (en) 2024-10-24

Family

ID=88834684

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023273853A Pending AU2023273853A1 (en) 2022-05-18 2023-05-17 Anti-b7h3 antibody and uses thereof

Country Status (12)

Country Link
US (1) US20250313633A1 (cg-RX-API-DMAC7.html)
EP (1) EP4526346A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025517737A (cg-RX-API-DMAC7.html)
KR (1) KR20250011957A (cg-RX-API-DMAC7.html)
CN (1) CN119256010A (cg-RX-API-DMAC7.html)
AU (1) AU2023273853A1 (cg-RX-API-DMAC7.html)
CA (1) CA3253563A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024003486A1 (cg-RX-API-DMAC7.html)
IL (1) IL316510A (cg-RX-API-DMAC7.html)
MX (1) MX2024014232A (cg-RX-API-DMAC7.html)
TW (1) TW202402808A (cg-RX-API-DMAC7.html)
WO (1) WO2023222017A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118829656B (zh) * 2023-12-01 2026-04-24 苏州智核生物医药科技有限公司 B7h3结合多肽及其用途
WO2025157244A1 (zh) * 2024-01-25 2025-07-31 山东先声生物制药有限公司 抗b7h3抗体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012501751A1 (en) * 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
KR102485788B1 (ko) * 2014-08-27 2023-01-09 메모리얼 슬로안 케터링 캔서 센터 항체, 조성물 및 용도
CA3056474A1 (en) * 2017-03-31 2018-10-04 Jiangsu Hengrui Medicine Co., Ltd. B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
KR102732027B1 (ko) * 2019-07-09 2024-11-20 주식회사 와이바이오로직스 B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도
CN111662384B (zh) * 2020-06-30 2021-04-09 广州百暨基因科技有限公司 抗b7h3抗体及其应用
CN113402610B (zh) * 2021-06-09 2023-02-24 英诺湖医药(杭州)有限公司 一组b7h3单克隆抗体及其医药用途
CN113336851B (zh) * 2021-06-30 2021-12-24 徐州医科大学 新型全人源抗人b7h3抗体、包含所述抗体的组合物及其应用

Also Published As

Publication number Publication date
MX2024014232A (es) 2025-03-07
US20250313633A1 (en) 2025-10-09
TW202402808A (zh) 2024-01-16
CN119256010A (zh) 2025-01-03
IL316510A (en) 2024-12-01
JP2025517737A (ja) 2025-06-10
KR20250011957A (ko) 2025-01-22
CA3253563A1 (en) 2023-11-23
CL2024003486A1 (es) 2025-06-13
EP4526346A1 (en) 2025-03-26
WO2023222017A1 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
US20240301067A1 (en) Novel anti-pd-1 antibodies
WO2019228406A1 (en) A novel anti-cd3/anti-cd20 bispecific antibody
EP4378954A1 (en) Anti-pvrig/anti-tigit bispecific antibody and application
US20230242645A1 (en) A bispecific anti-pd-l1/vegf antibody and uses thereof
TW202140546A (zh) 一種雙特異性抗pd-l1/vegf抗體及其用途
US12570746B2 (en) Anti-PD-L1 antibodies
US20250277054A1 (en) Psma antibodies and uses thereof
WO2023222017A1 (en) Anti-b7h3 antibody and uses thereof
WO2021057930A1 (en) A novel anti-pd-l1/anti-lag-3 bispecific antibody and uses thereof
WO2022206843A1 (en) A bispecific anti-pd-l1/vegf antibody and uses thereof
WO2021169986A1 (en) A bifunctional fusion protein and uses thereof
US20240376194A1 (en) D3-binding molecules and uses thereof
WO2022121966A1 (en) An antibody against p-cadherin and uses thereof
WO2026037400A1 (en) Anti-msln antibodies and uses thereof
WO2024251140A1 (en) Anti-tigit antibodies and uses thereof
WO2024251160A1 (en) Anti-pvrig antibodies and uses thereof
WO2024146553A1 (en) Antibodies against cd47, method for preparing the same, and use thereof
HK40117348A (en) Anti-b7h3 antibody and uses thereof